Sutro Biopharma launches $75M common stock offering at $5.18/share

SUTRO BIOPHARMA, INC.

14,478,764 shares offered at $5.18/share; gross proceeds ~$75M.
Underwriting agreement with BofA Securities; closing expected April 4, 2024.
Net proceeds for general corporate purposes including R&D and working capital.
Offering is dilutive to existing shareholders; trading symbol STRO on Nasdaq.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SUTRO BIOPHARMA, INC. entered into Underwriting Agreement with BofA Securities, Inc. (effective 2024-04-02).

Action: entry
Agreement: underwriting
Counterparty: BofA Securities, Inc.
Effective: 2024-04-02

Exact text from the filing

On April 2, 2024, Sutro Biopharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., as representative of the several underwriters named therein (the “Underwriter”), pursuant to which the Company agreed to issue and sell 14,478,764 shares of its common stock (the “Shares”) to the Underwriter (the “Offering”).

View on SEC.gov

380 material agreements filed in the last 30 days. Browse all material agreements →

SUTRO BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-040345

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.